Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy-Reference-Cited by-同舟云学术

Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy

Published:2021-03-10 Issue:7 Volume:206 Page:1561-1568
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Tedesco Victor E.^ORCID,Mohan Chandra

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference55 articles.

1. Chimeric Antigen Receptor Therapy

2. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

3. Brentjens, R. J. M. L. Davila I. Riviere J. Park X. Wang L. G. Cowell S. Bartido J. Stefanski C. Taylor M. Olszewska . 2013. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5: 177ra38.

4. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

5. United States Food and Drug Administration. 2017. FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. Washington D.C.: United States Food and Drug Adminstration. News Release. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy;Frontiers in Immunology;2024-09-12

2. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

3. Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma;Cancer Immunology, Immunotherapy;2024-08-02

4. Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy;Immunotherapy;2024-07-17

5. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy;Seminars in Immunopathology;2024-07-16